Railway Pension Investments Ltd Has $27.18 Million Position in Amgen Inc. $AMGN

Railway Pension Investments Ltd raised its stake in Amgen Inc. (NASDAQ:AMGN) by 9.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,300 shares of the medical research company’s stock after acquiring an additional 8,200 shares during the period. Railway Pension Investments Ltd’s holdings in Amgen were worth $27,176,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sandy Cove Advisors LLC lifted its stake in Amgen by 4.9% during the third quarter. Sandy Cove Advisors LLC now owns 1,487 shares of the medical research company’s stock worth $420,000 after purchasing an additional 70 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in Amgen by 2.9% in the 3rd quarter. Asset Management One Co. Ltd. now owns 350,514 shares of the medical research company’s stock valued at $98,915,000 after buying an additional 9,753 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its position in Amgen by 10.0% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 9,268 shares of the medical research company’s stock worth $2,615,000 after buying an additional 845 shares during the period. Penobscot Investment Management Company Inc. raised its position in Amgen by 0.5% during the 3rd quarter. Penobscot Investment Management Company Inc. now owns 16,784 shares of the medical research company’s stock worth $4,736,000 after purchasing an additional 79 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in Amgen by 6.0% during the 3rd quarter. Global Retirement Partners LLC now owns 16,380 shares of the medical research company’s stock worth $4,622,000 after buying an additional 928 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AMGN. Truist Financial initiated coverage on Amgen in a research note on Monday, November 24th. They issued a “hold” rating and a $318.00 price objective on the stock. Guggenheim increased their price target on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. The Goldman Sachs Group reissued a “buy” rating on shares of Amgen in a research note on Tuesday, November 25th. Argus increased their price target on Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Finally, Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $335.35.

Amgen Stock Performance

AMGN opened at $327.64 on Monday. Amgen Inc. has a 1-year low of $257.05 and a 1-year high of $346.38. The company has a market cap of $176.43 billion, a price-to-earnings ratio of 25.32, a PEG ratio of 2.98 and a beta of 0.45. The company’s fifty day moving average price is $326.08 and its two-hundred day moving average price is $302.97. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the company earned $5.58 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is 73.57%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is owned by insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.